Sherlock Biosciences, Inc. news
The 221b Foundation, a nonprofit organization established by Sherlock Biosciences to address the global COVID-19 pandemic while promoting diverse representation in STEM, today announced that it has granted a license to ALBOT USA and ALBOT Technologies Private Limited India to develop, manufacture and distribute COVID-19 diagnostic tests using Sherlock’s CRISPR technology. ALBOT has current capacity to manufacture up to 3
The 221b Foundation, a nonprofit organization established by Sherlock Biosciences to address the global COVID-19 pandemic while promoting diverse representation in STEM, today announced that it has granted Cooper International and United PPE licenses to develop and manufacture COVID-19 diagnostic tests using Sherlock’s CRISPR technology. The agreements will increase access in Asia and the Middle East.
By p
The 221b Foundation, a nonprofit organization established by Sherlock Biosciences to address the global COVID-19 pandemic and diverse representation in STEM, today announced an initiative with the Ministry of Health and Population (MoHP) in Nepal to control the spread of SARS-CoV-2 throughout the country. With contributions from Sherlock Biosciences, Open Philanthropy, Integrated DNA Technologies and MoHP, The 221b Foundation will provide support to the country of Nepal through financial assi
Sherlock Biosciences, an Engineering Biology company dedicated to making diagnostic testing better, faster and more affordable, today announced it has received a grant from the Bill & Melinda Gates Foundation in the amount of $5 million to continue to advance INSPECTRTM, its instrument-free, synthetic biology-based molecular diagnostics platform.
“We are deeply grateful for the support of the Gates Foundation as we seek to empower individuals all over the world
Sherlock Biosciences, an Engineering Biology company dedicated to making diagnostic testing better, faster and more affordable, today announced the formation of The 221b Foundation, a nonprofit organization committed to addressing the global COVID-19 pandemic by enabling access to intellectual property associated with the company’s SHERLOCK™ CRISPR-based technology. Proceeds from any company or third-party sales of SHERLOCK CRISPR COVID-19 products will support racial and gender d